(S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine hydrochloride | 1011465-95-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine hydrochloride
• 英文别名: ripasudil hydrochloric acid；4-fluoro-5-[[(2S)-2-methyl-1,4-diazocan-1-yl]sulfonyl]isoquinoline
• CAS: 1011465-95-4
• 化学式: C₁₆H₂₀FN₃O₂S
• 分子量: 337.418
• InChiKey: LBPBSQNQVMXJOY-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  70.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (S)-octahydro-4-(tert-butoxycarbonyl)-1-(4-fluoroisoquinoline-5-sulfonyl)-2-methyl-1,4-diazocine 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 反应 8.0h， 以86%的产率得到(S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine hydrochloride
  参考文献：
  名称：

  CN106496189

  摘要：

  公开号：

文献信息

• Therapeutic agent for treating glaucoma
  申请人：Hidaka Hiroyoshi

  公开号：US20080064681A1

  公开（公告）日：2008-03-13

  The present invention provides compounds useful as therapeutic agent for treating glaucoma and methods for treating glaucoma. That is, a therapeutic agent for treating glaucoma containing, as an active ingredient, a compound represented by formula (1) below is synthesized, and the therapeutic agent is administered in the form of eye drops to a glaucoma patient. Thus, the intraocular pressure is reduced. In the above formula, ring A represents a 5- to 11-membered cyclic amino group, which may have a substituted group, and X represents a halogen.

  本发明提供了作为治疗青光眼的治疗剂的化合物，以及治疗青光眼的方法。也就是说，合成了一种作为有效成分的化合物，其化学式如下所示，并且将这种治疗剂以眼药水的形式给青光眼患者使用。因此，眼内压得到了降低。在上述化学式中，环A代表一个5至11元环的氨基团，可能带有取代基，X代表一个卤素。
• ALISKIREN MODULATION OF NEUROGENESIS
  申请人：Barlow Carrolee

  公开号：US20090197823A1

  公开（公告）日：2009-08-06

  The disclosure provides compositions and methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis by use of a renin inhibitor in combination with one or more neurogenic agents. The disclosure also includes compositions and methods for stimulating or activating the formation of new nerve cells based on the application of a renin inhibitor in combination with one or more neurogenic agents.
• [EN] ALISKIREN MODULATION OF NEUROGENESIS<br/>[FR] MODULATION DE LA NEUROGENÈSE AVEC L'ALISKIREN
  申请人：BRAINCELLS INC

  公开号：WO2010111136A2

  公开（公告）日：2010-09-30

  The disclosure provides compositions and methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis by use of a renin inhibitor in combination with one or more neurogenic agents. The disclosure also includes compositions and methods for stimulating or activating the formation of new nerve cells based on the application of a renin inhibitor in combination with one or more neurogenic agents.